ARTICLE | Finance
Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C
RA Capital leads round to advance two programs towards IND
August 26, 2020 1:42 AM UTC
The presence of half a dozen crossover investors in Kinnate’s $98 million series C round suggests an IPO could be the next financing for the precision oncology company.
If it does go public this year before its lead BRAF inhibitor reaches the clinic, Kinnate Biopharma Inc. would join at least 14 other preclinical companies to debut in 2020; that’s on track to top the record of 16 set last year. The group has raised nearly $3 billion in total, according to BioCentury’s BCIQ database (see “Preclinical IPOs Attracting Big Money”)...
BCIQ Company Profiles